列万廷提出了基因、有机体、环境"三重螺旋"的概念，强调三者之间相互作用、相互影响的关系。 1990年3月，多伦多大学礼堂里座无虚席。享有盛名的遗传学家、进化生物学家R.C.列万廷（1929~2021）用一张玉米田的照片开场： " 把同样的种子撒进贫瘠与肥沃的土壤，你会看到截然不同的生长高度。请问，这是基因决定，还是土地决定？ " 台下没有统一答案——这正是列万廷想要的效果。 列万廷是受加拿大广播公司之邀，主讲了5场"梅西讲座"。讲稿1992年被整理成《作为意识形态的生物学》一书，中文版直到2022年才面世，却像把30年前 的火种直接扔进21世纪20年代的舆论干草堆：基因彩票、智商基因、犯罪遗传学、祖源测试、人类起源非洲说……话题越热，争议越尖锐。 列万廷攻击的对象，主要就是基因决定论，这乍看有点奇怪——作为世界知名、屡获大奖的遗传学家，率先将分子工具引入生物学的大拿，他显然非常了解 基因对生物的重要性。在《作为意识形态的生物学》中，列万廷只轻描淡写地点了理查德•道金斯一次名，可能道金斯的《自私的基因》在他看来只是一部 不那么合格的大众科普书，相比之下，他更愿意和老同事威尔逊论战，并集中火力攻击当时引起极大关注 ...

Core Viewpoint - The global beauty industry is facing growth bottlenecks, and Beiersdorf is not immune to this trend, as indicated by its recent financial report for the first half of 2025, which reveals performance slowdowns, profit pressures, and brand performance disparities [2][4]. Financial Performance - Beiersdorf reported revenue of €5.188 billion (approximately ¥434.45 billion), a year-on-year increase of 0.2% (organic growth of 2.1%), which is a significant slowdown compared to last year's 4.3% (organic growth of 7.1%) [8]. - The consumer goods segment, which accounts for over 80% of total revenue, generated €4.33 billion (approximately ¥362.6 billion), remaining flat year-on-year (organic growth of 1.9%) [8]. Brand Performance - The Derma brand continues to act as a "growth engine," with strong performances from Eucerin and Aquaphor driving a growth of 10.5% (organic growth of 12.2%) [10]. - Conversely, the luxury skincare brand La Prairie saw a decline of 10.8% (organic decline of 10.7%), despite achieving 3% growth in China during Q2, reflecting the broader trend of low demand in the global high-end market [10]. - Nivea, the largest brand in the consumer segment, experienced a decline of 1.2% (organic growth of 1.0%), indicating a critical period of brand adjustment [10]. Strategic Adjustments - Beiersdorf has lowered its full-year guidance for 2025, adjusting the organic sales growth target from 4-6% to approximately 3%, and the EBIT margin expectation from a 50 basis point increase to a 20 basis point increase [12]. - The company is focusing on innovation to drive growth, with plans for a significant new product launch from Nivea, the "Epigenetic Essence," set to launch in September across 30 countries [19][20]. Market Dynamics in China - In China, Beiersdorf has shown significant structural adjustments and channel breakthroughs, with La Prairie achieving 3% organic growth, primarily driven by a 36% surge in e-commerce sales [15][26]. - Nivea is undergoing structural adjustments, particularly in lower-tier cities, where it is shifting from low-margin products to higher-end offerings, aiming to better align with consumer preferences [17]. - The upcoming launch of Nivea's epigenetic essence is expected to be the largest product launch in the company's history, with a price point 40-50% lower than Eucerin, aiming to capture a larger consumer base [19][20]. Future Outlook - Beiersdorf's growth in China will depend on its ability to penetrate core segments and compete effectively against rivals in terms of efficiency and content [22]. - The company is strategically focusing on the skincare segment, reducing low-margin SKUs, and introducing innovative products to attract a broader consumer base [22][24]. - The successful performance of Eucerin and the recovery of La Prairie in the e-commerce space are seen as positive indicators for future growth [20][26].

Core Viewpoint - The Chinese Academy of Sciences' Institute of Biophysics plans to invest a total of 83.01 million yuan in the construction of three national key laboratories focusing on epigenetic regulation, biomolecules, and cognitive science and mental health [2][10]. Group 1: Epigenetic Regulation and Intervention National Key Laboratory - The Epigenetic Regulation and Intervention National Key Laboratory was approved on January 18, 2023, and aims to address major scientific issues in epigenetics, particularly related to significant diseases and aging [3]. - The laboratory's mission includes gathering influential talent to lead the international forefront of epigenetics and fill gaps in the national innovation system [3]. - Key research directions include chromatin structure and epigenetic regulation mechanisms, phylogenetic and homeostatic epigenetic mechanisms, and chromatin regulation related to aging and disease [6]. Group 2: Biomolecule National Key Laboratory - The Biomolecule National Key Laboratory, established in 1989, has consistently received excellent evaluations and focuses on proposing new questions and discovering new phenomena in life sciences [7]. - The laboratory aims to break through key technological bottlenecks and establish a complete research chain for drug target identification and vaccine design [7]. - Research will focus on supramolecular assembly rules, structure-based biomolecule simulation and design, and elucidating the dynamics of the endomembrane system [7]. Group 3: Cognitive Science and Mental Health National Key Laboratory - The Cognitive Science and Mental Health National Key Laboratory was restructured from the former National Key Laboratory of Brain and Cognitive Science and aims to explore cognitive neuroscience mechanisms related to mental health [9]. - The laboratory will focus on understanding the emergence of consciousness and its assessment, as well as precise adjustments for mental health [12]. - Key research directions include mechanisms of consciousness emergence, assessment of abnormal states of consciousness, and precise mental health adjustments [12].

Core Viewpoint - MD Anderson Cancer Center is recruiting postdoctoral researchers to advance cutting-edge single-cell multi-omics technologies and explore molecular regulatory networks in cancer development and drug resistance [3][8]. Group 1: Research Focus - The laboratory aims to develop single-cell multi-omics technologies, investigate the epigenetic regulatory mechanisms of cancer cell plasticity, and understand the epigenetic basis of individualized drug responses [3]. - The research group is led by Dr. Zhang Bingjie, who has a strong background in epigenomics and single-cell multi-omics [2]. Group 2: Institutional Overview - MD Anderson Cancer Center is a leading cancer treatment and research institution, consistently ranked as the top cancer specialty by U.S. News & World Report, located in Houston, Texas [8]. - The center has conducted over 1,680 clinical trials in 2024, with 22 drugs approved by the FDA and research funding amounting to $1.1 billion [8]. Group 3: Application Requirements - The position is for two postdoctoral researchers in genomics and tumor biology, requiring a Ph.D. in relevant biological fields [9][10]. - Candidates with backgrounds in tumor biology, genomics, and computational biology are preferred, along with strong communication and teamwork skills [10][11].

Financial Data and Key Metrics Changes - In 2024, the company recorded $1.2 million in revenue, a growth of 59% over 2023 [28] - Revenue from the NUQ VET cancer test was $0.8 million, growing by 75% compared to the prior year [28] - Operating expenses were reduced by 23% year-on-year, with second half operating expenses down 31% [30] - Net cash used in operating activities was $25.9 million in 2024, compared to $18.1 million in 2023 [31] Business Line Data and Key Metrics Changes - Approximately 120,000 NUQ VET cancer tests were sold in 2024, more than double the sales in 2023 [28] - Revenue from the NUQ Discover pillar was approximately $400,000, with a year-on-year growth of 40% [29] - The company recorded its first revenue from the NUQ NETS, marking a significant milestone [29] Market Data and Key Metrics Changes - The NUQ VET cancer test is now available in over 20 countries, expanding access significantly [18] - The point-of-care market is noted to be less than 20% of the total market, indicating growth potential [22] Company Strategy and Development Direction - The company aims to sign multiple licensing deals in 2025, focusing on human applications of its technology [11] - There is a strong interest in potential out-licensing and supply agreements for both NUQ NETS and the oncology portfolio [12] - The strategy includes raising non-dilutive funds, ramping revenues, reducing expenses, and signing commercial deals with large industry players [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash neutrality on a full-year basis by 2025 [27] - The company is at a pivotal juncture, ready to revolutionize diagnostics for both animals and humans [12] - Management highlighted the importance of automation in centralized labs to accelerate growth [22] Other Important Information - The company received approximately $1.8 million in non-dilutive funding from Belgian institutions during 2024 [33] - The NUQ platform has shown broad applicability across various established platforms, enhancing its market potential [14] Q&A Session Summary Question: Update on the feline cancer testing program - Management confirmed that the feline cancer testing program is on track for completion later this year, with a milestone payment of $5 million expected upon completion [80] Question: Discussion on the Leon study and its implementation - Management indicated that there are plans for prospective studies following the results of the Leon study, with potential rapid adoption in cancer programs [86][90] Question: Insights on quarterly sales trends and outlook for 2025 - Management noted that sales were lumpy due to large customers ordering in batches, but solid growth was achieved with 120,000 tests sold [100] - Automation in central labs is expected to open up larger opportunities in 2025 [101] Question: Approach to managing financing risks - Management emphasized a tight grip on expenses and cash flows while focusing on securing licensing agreements [112] Question: Activity and interest in data rooms for licensing agreements - Management reported that the data generated exceeded expectations and has been crucial in energizing discussions with major companies [118]